XORTX Therapeutics Inc (XRTX) FinancialsXRTXXORTX Therapeutics Inc

Evaluating the bottom line, XORTX Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -99.24%, provide a clear picture of how effectively XRTX converts its operational activities into shareholder value.

In the context of the broader market, XRTX competes directly with industry leaders such as KAPA and GNPX. With a market capitalization of $1.58M, it holds a significant position in the sector. When comparing efficiency, XRTX's gross margin of N/A stands against KAPA's N/A and GNPX's N/A. Such benchmarking helps identify whether XORTX Therapeutics Inc is trading at a premium or discount relative to its financial performance.

XORTX has reported consistent financial losses, with a net income of -1,690,734 USD in Q2 2026 and a gross profit of -17,852 USD, indicating significant operational challenges. The company's EPS has also been negative, with a figure of -1.05 in Q2 2026.